Nusigran Tablet contains Granisetron 1mg, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, and postoperative conditions. Granisetron acts by blocking serotonin receptors located centrally in the chemoreceptor trigger zone and peripherally in the gastrointestinal tract, thereby inhibiting the initiation of the vomiting reflex. Nusigran is indicated for patients undergoing highly emetogenic cancer treatments, providing effective control of acute and delayed nausea and vomiting. The tablet formulation allows for convenient oral administration, with rapid absorption and onset of action. It is generally well-tolerated, with common adverse effects including headache, constipation, and fatigue. Caution is advised in patients with hepatic impairment, as metabolism occurs primarily in the liver. Dosage adjustments may be necessary based on clinical response and patient condition. Nusigran should be used under medical supervision, with attention to potential drug interactions, especially with other serotonergic agents. This medication significantly improves patient quality of life during cancer therapy by reducing emetic episodes and associated complications, thereby facilitating adherence to prescribed treatment regimens.